Lantern Pharma Inc. (Nasdaq: LTRN)
Lantern Pharma Inc. is a biotechnology company specializing in precision oncology drug development. Utilizing its proprietary AI platform, RADR®, the company focuses on creating targeted therapies for cancer patients. Its customers include healthcare providers and pharmaceutical firms seeking innovative solutions to enhance cancer treatment efficacy. Lantern Pharma operates through clinical trials and research collaborations to advance its drug candidates.
Headcount
Website visitors
Workforce
Headcount by location
- United States93%
- India7.1%
Split by department
- Engineering & R&D30%
- Healthcare26%
- Finance & Administration13%
- Founder, Owner & Executive8.7%
- Other22%
Seniority distribution
- Less than 5 years67%
- 5 to 10 years19%
- 10 to 20 years14%
Funding
Raised to date
- 13 May 2026Post Ipo Equity Offering$4.4M—
- 20 Jan 2021IpoUndisclosed—
5 earlier rounds, with their terms and sources.
Investors
Green Park & Golf VenturesGreen Park & Golf Ventures is a venture capital firm that focuses on investing in medical-related start-ups. The company provides financial backing and strategic solutions to entrepreneurs, helping them navigate the complexities of the healthcare46United States
Bios PartnersBios Partners is a venture capital firm specializing in biotechnology investments. The firm identifies and cultivates advanced biotech companies in under-invested markets, particularly in the Central U.S. They provide capital and operational support16United States
- Biological Mimetics, Inc.Biological Mimetics, Inc. is a biomedical company specializing in the development of innovative pharmaceutical products and technologies aimed at improving public health. The company focuses on vaccine development and rapid diagnostics for1United States
Revenue
EBITDA
Revenue source: Public reported FY2025 (Stock exchange)
Recent news
- NetworkNewsBreaks - Lantern Pharma (NASDAQ: LTRN) to host webinar on Open-Medicine AI platform, business model and development roadmap.is developing
- Lantern Pharma to report second quarter 2026 operating & financial results on August 14th, 2026 at 9.expands facilities
- Lantern Pharma launches zetaomics(tm)- an autonomous, Intelligent "computational Biologist" That brings expert-grade bioinformatics, biostatistics & reasoning to every cancer.launches
- Lantern Pharma unveils ZetaSwarm multi-agentic co-scientist platform.launches
People
How the team has changed month by month — joiners, leavers and where the hiring is going
Connections
Who at your firm already knows someone here, and how warm the path is
The full Lantern Pharma Inc. (Nasdaq: LTRN) profile lives in Inven.
Your competitors are already on Inven
See how Inven turns hours of manual research into a single, structured workflow.